Pfizer/Wyeth Merger Would Offer Diversification, Switch Outlet
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's potential acquisition of Wyeth could swing the company back to a diversified portfolio - including the return of a consumer health division -and help offset a dwindling pipeline and the looming generic competition that threatens Rx sales, analysts say
You may also be interested in...
Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years
Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years
Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014
French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years